RSS-Feed abonnieren
DOI: 10.1055/s-2007-970179
The Efficacy and Safety of Early Supplementation of Iron Polymaltose Complex in Preterm Infants
Publikationsverlauf
Publikationsdatum:
15. Februar 2007 (online)
![](https://www.thieme-connect.de/media/ajp/200702/lookinside/thumbnails/10.1055-s-2007-970179-1.jpg)
ABSTRACT
The purpose of this study was to examine the efficacy and safety of early nonionic iron supplementation in preterm infants. Infants with gestational age ≤ 32 weeks who were fed enriched human milk were assigned concurrently to receive 5 mg/kg/d enteral iron polymaltose complex (IPC) at 2 or 4 weeks of age. The levels of hemoglobin, reticulocytes, serum iron, ferritin, and soluble transferrin receptor were recorded at 2, 4, and 8 weeks of age. The incidence of morbidities associated with prematurity and the need for red blood cell transfusions (RBCTs) were recorded. The 2-week group (n = 32) had a better iron status than the 4-week group (n = 36) at 4 weeks and at 8 weeks of age. The incidence of morbidities associated with prematurity was not different among the groups (p = 0.26). RBCT was required in one infants of the 2-week group and in 10 infants in the 4-week group (p = 0.045). The number needed to treat to prevent one RBCT was five. Supplementation of 5 mg/kg/d enteral IPC to preterm infants fed enriched human milk as early as 2 weeks of age was more beneficial to iron status than at 4 weeks of age, and was associated with decreased need for RBCTs and no increase in the incidence of morbidities associated with prematurity.
KEYWORDS
Preterm infants - iron supplementation - morbidities associated with prematurity - iron polymaltose complex
REFERENCES
- 1 Roth P. Anemia in preterm infants. Pediatr Rev. 1996; 17 370
- 2 American Academy of Pediatrics Committee on Nutrition . Nutritional needs of low-birth-weight infants. Pediatrics. 1985; 75 976-986
- 3 Franz A R, Mihatsch W A, Sander S, Kron M, Pohlandt F. Prospective randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams. Pediatrics. 2000; 106 700-706
- 4 Inder T E, Clemett R S, Austin N C, Graham P, Darlow B A. High iron status in very low birth weight infants is associated with an increased risk of retinopathy of prematurity. J Pediatr. 1997; 131 541-544
- 5 Tuomainen T P, Nyyssonen K, Porkkala-Sarataho E et al.. Oral supplementation with ferrous sulfate but not with non-ionic iron polymaltose complex increase the susceptibility of plasma lipoproteins to oxidation. Nutr Res. 1999; 19 1121-1132
- 6 Franz A R, Pohlandt F. Red blood cell transfusions in very and extremely low birthweight infants under restrictive transfusion guidelines: is exogenous erythropoietin necessary?. Arch Dis Child Fetal Neonatal Ed. 2001; 84 F96-F100
- 7 Jew R K, Owen D, Kaufman D, Balmer D. Osmolarity of commonly used medications and formulas in the neonatal intensive care unit. Nutr Clin Pract. 1997; 12 158-163
- 8 Sweet D G, Savage G A, Tubman R, Lappin T R, Halliday H L. Cord blood transferrin receptors to assess fetal iron status. Arch Dis Child Fetal Neonatal Ed. 2001; 85 F46-F48
- 9 Lundstrom U, Siimes M A, Dallman P R. At what age does iron supplementation become necessary in low-birth-weight infants?. J Pediatr. 1977; 91 878-883
- 10 Hall R T, Wheeler R E, Benson J, Harris G, Rippetoe L. Feeding iron-fortified premature formula during initial hospitalization to infants less than 1800 grams birth weight. Pediatrics. 1993; 92 409-414
-
11 Rao R, Georgieff M.
Microminerals . In: Tsang RC, Uauy R, Koletzko B, Zlotkin S Nutrition of the Preterm Infant: Scientific Basis and Practical Guidelines. 2nd ed. Cincinnati, OH; Digital Educational Publishing 2005: 271-288 - 12 Turker G, Sarper N, Gokalp A S, Usluer H. The effect of early recombinant erythropoietin and enteral iron supplementation on blood transfusion in preterm infants. Am J Perinatol. 2005; 22 449-455
- 13 Rudzinska I M, Kornacka M K, Pawluch R. Treatment with human recombinant erythropoietin and frequency of retinopathy of prematurity. Przegl Lek. 2002; 59(suppl 1) 83-85
- 14 Ohlsson A, Aher S. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev. 2006; (19) CD004863
- 15 Johnson G, Jacobs P. Bioavailability and the mechanisms of intestinal absorption of iron from ferrous ascorbate and ferric polymaltose in experimental animals. Exp Hematol. 1990; 18 1064-1069
- 16 Erichsen K, Ulvik R J, Grimstad T, Berstad A, Berge R K, Hausken T. Effects of ferrous sulphate and non-ionic iron-polymaltose complex on markers of oxidative tissue damage in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2005; 22 831-838
- 17 Buonocore G, Perrone S, Bracci R. Free radicals and brain damage in the newborn. Biol Neonate. 2001; 79 180-186
- 18 Kuiper-Kramer E P, Baerts W, Bakker R, van Eyck J, van Raan J, van Eijk H G. Evaluation of the iron status of the newborn by soluble transferrin receptors in serum. Clin Chem Lab Med. 1998; 36 17-21
- 19 Melhorn D K, Gross S. Vitamin E-dependent anemia in the premature infant. I. Effects of large doses of medicinal iron. J Pediatr. 1971; 79 569-580
Shmuel ArnonM.D.
Department of Neonatology, Meir Medical Center, Kfar Saba
44281, Israel